We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Asterand to Integrate its Quantitative Human Gene Expression Database with BioWisdom’s Integrated Discovery Platform

Want a FREE PDF version of this news story?

Complete the form below and we will email you a PDF version of "Asterand to Integrate its Quantitative Human Gene Expression Database with BioWisdom’s Integrated Discovery Platform"

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.
Read time:
Asterand plc and BioWisdom Ltd have announced that the Companies have entered into a data syndication agreement to provide value added delivery of Asterand’s human gene expression profiles through BioWisdom’s intelligence solutions. Terms of the agreement were not disclosed.

Through this agreement, BioWisdom gains access to the data within Asterand’s proprietary Target Evaluator™ database. The database consists of quantitative human gene expression profiles that chart the expression topography of more than 2,500 commercially relevant gene transcripts across a panel of 72 human tissues. These profiles are systematically generated using high quality human RNA and a sensitive RT-PCR protocol.

BioWisdom will harmonize the data with its software solutions enabling the information to be combined with other public and private sources or utilized independently as raw data or assertional meta data. The harmonized Asterand data are available as an entire dataset or sub-sets of selected targets and tissues.

BioWisdom’s ontology powered intelligence solutions ease the integration and display of data enabling researchers to visually analyze text, numerical, categorical and sequence data in a single integrated environment. As a result, researchers are able to relate divergent data sets to uncover previously unknown associations and answer key scientific questions.